Qualys reported strong Q2 2026 results, with earnings per share of $1.98 surpassing the $1.78 consensus and revenue of $182.2 million, an 11% year-over-year increase. The company raised its full-year 2026 revenue guidance to $732-$738 million, reflecting confidence in its cybersecurity solutions and AI-driven innovations. Qualys also shows strong financial health with low debt and good liquidity, supporting its growth outlook in the competitive cybersecurity market.
Bunge Global SA saw a director purchase 1,500 shares at $107.60, signaling insider confidence. Analysts have set a mean price target of $138.30, implying a 28.3% upside, driven by strong Q2 performance in soybeans and softseeds that raised earnings o...
Stocks fell sharply due to various factors including a 58.71% drop in the Defiance Daily Target 2x Short PLTR ETF, driven by strong gains in Palantir Technologies, which the ETF inversely tracks. AdaptHealth shares dropped 38.09% amid a legal investi...
Pomerantz LLP is investigating Karyopharm Therapeutics for potential securities fraud related to a retention program granting top executives lump sum cash bonuses between $625,000 and $1,725,000. The announcement led to a 21.45% drop in Karyopharm's ...
LiveOne announced it will release its first quarter fiscal 2027 financial results on August 12, 2026, with a conference call to discuss the performance. The company expects continued year-over-year growth in revenue and adjusted EBITDA, driven by org...
Immix Biopharma appointed Richard Graydon as Chief Medical Officer in March 2026, but he was terminated in July after it was revealed he was actually Ronald L. Fischer, a fugitive wanted since 2005 for rape charges. This revelation led to a 14.15% dr...
